Diagnosis and Treatment for Hepatocellular Tumors
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, accounting for >80% of primary liver cancers worldwide. The diagnosis of HCC, relying solely on noninvasive criteria, is currently under debate due to the need for molecular information that necessitates tissue biopsies, whil...
Saved in:
| Format: | Online |
|---|---|
| Sprog: | engelsk |
| Udgivet: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Fag: | |
| Online adgang: | ONIX_20231130_9783036593203_187 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
| _version_ | 1869522892715196416 |
|---|---|
| collection | Directory of Open Access Books |
| description | Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, accounting for >80% of primary liver cancers worldwide. The diagnosis of HCC, relying solely on noninvasive criteria, is currently under debate due to the need for molecular information that necessitates tissue biopsies, while therapy is provided in accordance with tumor stages and the anticipated advantages of major interventions, following the Barcelona Clinic Liver Cancer (BCLC) staging system. Principally, resection, transplantation and local ablation are most commonly performed in patients with early-stage HCC tumors, while TACE and systemic therapy are, respectively, the preferred treatment options for intermediate- and advanced-stage tumors. However, the HCC tumor immune microenvironment (TME) affects the response to current anti-PD-1/PD-L1 immunotherapies. Therefore, an enhanced understanding of the immunobiology of TME is essential for the development of predictive biomarkers of patient stratification and strategies of drug combinations to improve therapeutic efficacy, especially for patients with tumors that are unresponsive to anti-PD-1/PD-L1 therapy. Taking into account the health burden of HCC worldwide, with this Special Issue, we aim to enhance our knowledge of innovative diagnostic and prognostic methods and to discuss experimentation with different novel treatment modalities, believed to be of the utmost priority to progress in our seemingly never-ending fight against hepatocellular cancer. |
| format | Online |
| id | doab-20.500.12854ir-128735 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1287352024-03-30T23:23:05Z Diagnosis and Treatment for Hepatocellular Tumors Germanidis, Georgios HCC hepatocellular tumors tumor microenvironment tumor-associated macrophages diagnosis treatment BCLC-B BCLC-C anti-PD-1/PD-L1 immunotherapy TKIs combinations addiction loops interventions established data future perspectives thema EDItEUR::M Medicine and Nursing Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, accounting for >80% of primary liver cancers worldwide. The diagnosis of HCC, relying solely on noninvasive criteria, is currently under debate due to the need for molecular information that necessitates tissue biopsies, while therapy is provided in accordance with tumor stages and the anticipated advantages of major interventions, following the Barcelona Clinic Liver Cancer (BCLC) staging system. Principally, resection, transplantation and local ablation are most commonly performed in patients with early-stage HCC tumors, while TACE and systemic therapy are, respectively, the preferred treatment options for intermediate- and advanced-stage tumors. However, the HCC tumor immune microenvironment (TME) affects the response to current anti-PD-1/PD-L1 immunotherapies. Therefore, an enhanced understanding of the immunobiology of TME is essential for the development of predictive biomarkers of patient stratification and strategies of drug combinations to improve therapeutic efficacy, especially for patients with tumors that are unresponsive to anti-PD-1/PD-L1 therapy. Taking into account the health burden of HCC worldwide, with this Special Issue, we aim to enhance our knowledge of innovative diagnostic and prognostic methods and to discuss experimentation with different novel treatment modalities, believed to be of the utmost priority to progress in our seemingly never-ending fight against hepatocellular cancer. 2023-11-30T20:47:51Z 2023-11-30T20:47:51Z 2023 book ONIX_20231130_9783036593203_187 9783036593203 9783036593210 https://directory.doabooks.org/handle/20.500.12854/128735 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/8199 https://mdpi.com/books/pdfview/book/8199 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-9321-0 10.3390/books978-3-0365-9321-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036593203 9783036593210 330 Basel open access |
| spellingShingle | HCC hepatocellular tumors tumor microenvironment tumor-associated macrophages diagnosis treatment BCLC-B BCLC-C anti-PD-1/PD-L1 immunotherapy TKIs combinations addiction loops interventions established data future perspectives thema EDItEUR::M Medicine and Nursing Diagnosis and Treatment for Hepatocellular Tumors |
| title | Diagnosis and Treatment for Hepatocellular Tumors |
| title_full | Diagnosis and Treatment for Hepatocellular Tumors |
| title_fullStr | Diagnosis and Treatment for Hepatocellular Tumors |
| title_full_unstemmed | Diagnosis and Treatment for Hepatocellular Tumors |
| title_short | Diagnosis and Treatment for Hepatocellular Tumors |
| title_sort | diagnosis and treatment for hepatocellular tumors |
| topic | HCC hepatocellular tumors tumor microenvironment tumor-associated macrophages diagnosis treatment BCLC-B BCLC-C anti-PD-1/PD-L1 immunotherapy TKIs combinations addiction loops interventions established data future perspectives thema EDItEUR::M Medicine and Nursing |
| topic_facet | HCC hepatocellular tumors tumor microenvironment tumor-associated macrophages diagnosis treatment BCLC-B BCLC-C anti-PD-1/PD-L1 immunotherapy TKIs combinations addiction loops interventions established data future perspectives thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20231130_9783036593203_187 |